Alexion's R&D Plans At Increased Pace With Rhythm Voucher
Follows Last Month's Acquisition Agreement With AstraZeneca
• By John Davis
Generate a summary of this article
Listen to this article
After last month’s news of its proposed acquisition by AstraZeneca, Alexion Pharmaceuticals has bought a priority review voucher from Rhythm Pharmaceuticals, which would speed one of its development projects towards the marketplace.
Speeding Development Plans • Source: Shutterstock
Alexion Pharmaceuticals Inc.’s attractions for its likely acquirer AstraZeneca PLC now include a rare pediatric disease priority review voucher (PRV), which Alexion is buying from Rhythm Pharmaceuticals, Inc. for $100m. Rhythm announced the sale on 5 January, when its share price rose by 4%.
AstraZeneca announced in the middle of last month that it was offering $39bn to acquire Alexion, with the deal expected...
Keep up with the top pharma business news of the week. On the go.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.
CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.